COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.
Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein
Advertisement
Articles by Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein
PIVOTAL (NCT02938299) is an open label, randomized, multicenter, phase 3 trial evaluating Daromun as a neoadjuvant intralesional therapy for resectable, locally advanced Stage III melanoma.
Advertisement
Latest Updated Articles
Molecular Testing in Metastatic MelanomaJanuary 22nd 2021
The Role of COVID-19 in Adjuvant Treatment Decisions in MelanomaJanuary 22nd 2021
Looking at Approved Agents in Metastatic MelanomaJanuary 29th 2021
Testing and BRAF Mutations in MelanomaJanuary 8th 2021
Future Directions in Metastatic MelanomaFebruary 5th 2021
A Look at the KEYNOTE-054 and COMBI-AD DataJanuary 15th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5